GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TheraCryf PLC (LSE:TCF) » Definitions » Momentum Rank

TheraCryf (LSE:TCF) Momentum Rank : 0 (As of Apr. 12, 2025)


View and export this data going back to 2015. Start your Free Trial

What is TheraCryf Momentum Rank?

TheraCryf has the Momentum Rank of 0.

Momentum Rank measures the strength and persistence of a stock's price movement over time, rated on a scale of 1 to 10.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

A higher score reflects strong price momentum and indicates greater potential for superior performance. Conversely, a lower score indicates that momentum is either too high or too low, and stocks tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.


TheraCryf Momentum Rank Related Terms

Thank you for viewing the detailed overview of TheraCryf's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


TheraCryf Business Description

Traded in Other Exchanges
N/A
Address
Congleton Road, Alderley Park, Nether Alderley, Cheshire, GBR, SK10 4TG
TheraCryf PLC is a clinical-stage biotechnology company focused on profitable segments in oncology and neuropsychiatry. The company's lead clinical asset, SFX-01 is a patented form of delivering sulforaphane, which could be used in the treatment of a number of cancers, neurodevelopmental disorders, and other diseases.

TheraCryf Headlines

From GuruFocus

TCF Financial Corporation Announces Date for Third Quarter 2020 Earnings

By Business Wire Business Wire 10-08-2020

TCF National Bank Acquires BB&T Commercial Equipment Capital, Corp.

By Business Wire Business Wire 02-01-2021

Tcf Financial Corp (TCF) EVP, CFO Brian W Maass Sold $1.1 million of Shares

By GuruFocus Research GuruFocus Editor 03-12-2021

Lindsay Yousif Named TCF Bank's Chief Compliance Officer

By Business Wire Business Wire 11-19-2020